Back to Search
Start Over
Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.
- Source :
-
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Aug; Vol. 22 (8), pp. 566-568. Date of Electronic Publication: 2022 Mar 09. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 2152-2669
- Volume :
- 22
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Clinical lymphoma, myeloma & leukemia
- Publication Type :
- Editorial & Opinion
- Accession number :
- 35367193
- Full Text :
- https://doi.org/10.1016/j.clml.2022.03.003